Abstract
Head and neck squamous cell carcinoma (HNSCC) comprise a diverse group of malignancies including tumors caused by tobacco and alcohol as well as an increasing number of human papillomavirus (HPV)-associated cancers. There has been recent improved understanding on how HNSCC develops by evading the immune system. The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to the checkpoint inhibitor pembrolizumab for the treatment of recurrent or metastatic HNSCC. We provide a comprehensive review of immune escape mechanism in HNSCC and latest developments in immunotherapy in HNSCC with a focus on checkpoint inhibitors, therapeutic cancer vaccines, and adoptive cellular therapies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 48-55 |
| Number of pages | 8 |
| Journal | Translational Cancer Research |
| Volume | 6 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2017 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© Translational Cancer Research. All rights reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Checkpoint inhibitor
- Head and neck cancer
- Immunotherapy
- Pembrolizumab
- Programmed cell death-1 (PD-1)
Fingerprint
Dive into the research topics of 'Immunotherapy in head and neck cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS